This review assesses the promise of nanoparticles containing melatonin and lactoferrin (ML-Lf-NPs) in treating cancer, concentrating on their capacity to improve drug delivery, pinpoint tumors, and optimize therapeutic efficacy. A thorough examination of recent progress in nanoparticle-oriented drug delivery systems was performed, highlighting the physicochemical characteristics, mechanisms of action, and biological interactions of ML-Lf-NPs. Melatonin nanoparticles demonstrate antioxidant and anti-inflammatory characteristics that enhance tumor targeting and therapeutic results. Lactoferrin nanoparticles show potential anticancer effects by improving cellular absorption and enabling targeted drug release at tumors. Both systems demonstrate considerable promise for enhancing drug bioavailability and minimizing side effects. ML-Lf-NPs signify creative strategies for cancer treatment. Their distinct characteristics allow for precise delivery and improved therapeutic effectiveness, opening doors for future clinical uses in cancer treatment.
AmmarOA, El-MissiryMA, OthmanAI, et al.Melatonin is a potential oncostatic agent to inhibit HepG2 cell proliferation through multiple pathways. Heliyon, 2022; 8(1):e08837; doi: 10.1016/j.heliyon.2022.e08837
2.
Fernández-PalancaP, Méndez-BlancoC, FondevilaF, et al.Melatonin as an antitumor agent against liver cancer: An updated systematic review. Antioxidants (Basel), 2021; 10(1):103; doi: 10.3390/antiox10010103
3.
HamedAR, YahyaSM, NabihHK. Anti-drug resistance, anti-inflammation, and anti-proliferation activities mediated by melatonin in doxorubicin-resistant hepatocellular carcinoma: In vitro investigations. Naunyn Schmiedebergs Arch Pharmacol, 2023; 396(6):1117–1128.
4.
MiL, KuangH. Melatonin regulates cisplatin resistance and glucose metabolism through hippo signaling in hepatocellular carcinoma cells. Cancer Manag Res, 2020; 12:1863–1874.
5.
CruzEMS, ConcatoVM, de MoraisJMB, et al.Melatonin modulates the Warburg effect and alters the morphology of hepatocellular carcinoma cell line resulting in reduced viability and migratory potential. Life Sci, 2023; 319:121530.
6.
SamecM, LiskovaA, KoklesovaL, et al.Metabolic anti-cancer effects of melatonin: Clinically relevant prospects. Cancers (Basel), 2021; 13(12):3018.
7.
SharmaN, KhatoonN, RazaMA, et al.A pioneer review on lactoferrin as versatile macromolecular ligand for targeting cancer: Recent advances. J Drug Target, 2025:1–19; doi: 10.1080/1061186X.2025.2529528
8.
ElmahallawyEK, MohamedY, AbdoW, et al.Melatonin and mesenchymal stem cells as a key for functional integrity for liver cancer treatment. Int J Mol Sci, 2020; 21(12):4521.
9.
PatelP, TrivediA, PrajapatiBG, et al.QbD- driven development and characterization of Lactoferrin-loaded nanoparticles in in-situ gel for treating postmenopausal osteoporosis. Next Research, 2025; 2(1):100142; doi: 10.1016/j.nexres.2025.100142
10.
ElbananME, AmerME, El-MissiryMA, et al.Melatonin protects mice from 5-FU hepatotoxicity and improves 5-FU antitumor effects by an apoptotic pathway dependent on cell cycle arrest in A549 human lung cancer cells. RPS Pharmacy and Pharmacology Reports, 2023; 2(4):rqad034.
11.
DulskasA, GaizauskasV, KildusieneI, et al.Improvement of survival over time for colorectal cancer patients: A population-based study. J Clin Med, 2020; 9(12):4038.
12.
LiY, FengA, ZhengS, et al.Recent estimates and predictions of 5-year survival in patients with gastric cancer: A model-based period analysis. Cancer Control, 2022; 29:10732748221099227.
13.
SantucciC, CarioliG, BertuccioP, et al.Progress in cancer mortality, incidence, and survival: A global overview. Eur J Cancer Prev, 2020; 29(5):367–381.
14.
HuangH, HuangF, LiangX, et al.Afatinib Reverses EMT via Inhibiting CD44-Stat3 Axis to Promote Radiosensitivity in Nasopharyngeal Carcinoma. Pharmaceuticals (Basel), 2022; 16(1):37; doi: 10.3390/ph16010037
15.
BogosK, KissZ, TamasiL, et al.Improvement in lung cancer survival: 6-year trends of overall survival at Hungarian patients diagnosed in 2011–2016. Pathol Oncol Res, 2021; 27:603937.
16.
LouY, ChengM, CaoQ, et al.Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder. J Pharm Biomed Anal, 2024; 240:115937; doi: 10.1016/j.jpba.2023.115937
17.
DuJ, MengX, YangM, et al.NGR-Modified CAF-Derived exos Targeting Tumor Vasculature to Induce Ferroptosis and Overcome Chemoresistance in Osteosarcoma. Adv Sci (Weinh), 2025; 12(12):e2410918; doi: 10.1002/advs.202410918
18.
RazaMA, KhatoonN, ParveenR, et al.Natural macromolecules polysaccharide-based drug delivery systems targeting tumor necrosis factor alpha receptor for the treatment of cancer: A review. Int J Biol Macromol, 2025; 318(Pt 4):145145; doi: 10.1016/j.ijbiomac.2025.145145
19.
YuanH, ChenY, HuY, et al.Disulfide bond-driven nanoassembly of lipophilic epirubicin prodrugs for breast cancer therapy. J Pharm Investig, 2025; doi: 10.1007/s40005-025-00731-z
20.
NieY, LiD, PengY, et al.Metal organic framework coated MnO(2) nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer. Int J Pharm, 2020; 585:119513; doi: 10.1016/j.ijpharm.2020.119513
21.
FengC, WangY, XuJ, et al.Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect. Pharmaceutics, 2024; 16(12):1582; doi: 10.3390/pharmaceutics16121582
22.
WangY, XuY, SongJ, et al.Tumor cell-targeting and tumor microenvironment-responsive nanoplatforms for the multimodal imaging-guided photodynamic/photothermal/chemodynamic treatment of cervical cancer. Int J Nanomedicine, 2024; 19:5837–5858; doi: 10.2147/ijn.S466042
23.
El MoukhtariSH, GarbayoE, AmundarainA, et al.Lipid nanoparticles for siRNA delivery in cancer treatment. J Control Release, 2023; 361:130–146; doi: 10.1016/j.jconrel.2023.07.054
24.
EdisZ, WangJ, WaqasMK, et al.Nanocarriers-mediated drug delivery systems for anticancer agents: An overview and perspectives. Int J Nanomedicine, 2021; 16:1313–1330.
25.
RavalH, BhattacharyaS, BhirudD, et al.Fabrication of lactoferrin-chitosan-etoposide nanoparticles with melatonin via carbodiimide coupling: In-vitro & in-vivo evaluation for colon cancer. J Control Release, 2025; 377:810–841; doi: 10.1016/j.jconrel.2024.11.077
26.
KooshanZ, SrinivasanS, JanjuaTI, et al.Lactoferrin conjugated radicicol nanoparticles enhanced drug delivery and cytotoxicity in prostate cancer cells. Eur J Pharmacol, 2025; 991:177300; doi: 10.1016/j.ejphar.2025.177300
27.
YangT, ZhangZ, ZhangJ, et al.Developing a Gallium(III) agent based on the properties of the tumor microenvironment and lactoferrin: Achieving two-agent co-delivery and multi-targeted combination therapy of cancer. J Med Chem, 2023; 66(1):793–803; doi: 10.1021/acs.jmedchem.2c01684
28.
ZayedDG, KhattabSN, HeikalL, et al.Tailored design of pH-responsive microbeads for oral delivery of lactoferrin nanotherapeutics of colon cancer. J Drug Deliv Sci Technol, 2024; 97:105791; doi: 10.1016/j.jddst.2024.105791
29.
Guevara-GarciaA, SoleilhacM, MincN, et al.Regulation and functions of cell division in the intestinal tissue. Semin Cell Dev Biol, 2023; 150–151:3–14.
30.
LiY, DengG, HuX, et al.Recent advances in mesoporous silica nanoparticle-based targeted drug-delivery systems for cancer therapy. Nanomedicine (Lond), 2022; 17(18):1253–1279; doi: 10.2217/nnm-2022-0023
31.
MajidpoorJ, MortezaeeK. Steps in metastasis: An updated review. Med Oncol, 2021; 38(1):3.
ZhangX-X, LuoJ-H, WuL-Q. FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer. Front Genet, 2022; 13:913659.
34.
Abd ElhamidAS, HeikalL, GhareebDA, et al.Engineering Thermo/pH-responsive lactoferrin nanostructured microbeads for oral targeting of colorectal cancer. ACS Biomater Sci Eng, 2024; 10(8):4985–5000; doi: 10.1021/acsbiomaterials.4c00666
35.
ElmorshedyYM, TelebM, SallamMA, et al.Engineered microencapsulated lactoferrin nanoconjugates for oral targeted treatment of colon cancer. Biomacromolecules, 2023; 24(5):2149–2163; doi: 10.1021/acs.biomac.3c00037
36.
El-FakharanyEM, El-MaradnyYA, AshryM, et al.Green synthesis, characterization, anti-SARS-CoV-2 entry, and replication of lactoferrin-coated zinc nanoparticles with halting lung fibrosis induced in adult male albino rats. Sci Rep, 2023; 13(1):15921.
37.
VaghasiyaK, RayE, SinghR, et al.Efficient, enzyme responsive and tumor receptor targeting gelatin nanoparticles decorated with concanavalin-A for site-specific and controlled drug delivery for cancer therapy. Mater Sci Eng C Mater Biol Appl, 2021; 123:112027; doi: 10.1016/j.msec.2021.112027
38.
LigorioF, FucàG, ZattarinE, et al.The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers (Basel), 2021; 13(8):1964.
39.
AndimaM, BoeseA, PaulP, et al.Targeting intracellular bacteria with dual drug-loaded lactoferrin nanoparticles. ACS Infect Dis, 2024; 10(5):1696–1710; doi: 10.1021/acsinfecdis.4c00045
40.
HuangWY, LaiCH, PengSL, et al.Targeting tumor cells with nanoparticles for enhanced co-drug delivery in cancer treatment. Pharmaceutics, 2021; 13(9):1327; doi: 10.3390/pharmaceutics13091327
41.
PatelSA, NilssonMB, LeX, et al.Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res, 2023; 29(1):30–39.
42.
MabetaP, SteenkampV. The VEGF/VEGFR axis revisited: Implications for cancer therapy. Int J Mol Sci, 2022; 23(24):15585.
43.
El-FakharanyEM, AshryM, Abd-ElaleemA-EH, et al.Therapeutic efficacy of Nano-formulation of lactoperoxidase and lactoferrin via promoting immunomodulatory and apoptotic effects. Int J Biol Macromol, 2022; 220:43–55.
44.
ZhiD, YangT, YangJ, et al.Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy. Acta Biomater, 2020; 102:13–34.
45.
CaoY, ZhangH, ChenX, et al.Melatonin: A natural guardian in cancer treatment. Front Pharmacol, 2025; 16:1617508; doi: 10.3389/fphar.2025.1617508
46.
León-FloresDB, Siañez-EstadaLI, Iglesias-FigueroaBF, et al.Anticancer potential of lactoferrin: Effects, drug synergy and molecular interactions. Biometals, 2025; 38(2):465–484; doi: 10.1007/s10534-025-00672-y
47.
Gil-MartínE, RamosE, López-MuñozF, et al.Potential of melatonin to reverse epigenetic aberrations in oral cancer: New findings. Excli J, 2023; 22:1280–1310; doi: 10.17179/excli2023-6624
48.
BolesławskaI, Bolesławska-KrólN, JakubowskiK, et al.Lactoferrin-A Regulator of Iron Homeostasis and Its Implications in Cancer. Molecules, 2025; 30(7):1507; doi: 10.3390/molecules30071507
49.
AttriK, ChudasamaB, MahajanRL, et al.Therapeutic potential of lactoferrin-coated iron oxide nanospheres for targeted hyperthermia in gastric cancer. Sci Rep, 2023; 13(1):17875; doi: 10.1038/s41598-023-43725-3
50.
BhattacharyaS, RavalH, BhirudD. Hyaluronic acid-functionalized carboxymethyl dextran-coated melatonin nanoconjugates for targeted etoposide delivery in metastatic colon cancer: Extensive in-vitro investigation in HCT116 cell lines, antimicrobial efficacy, and anti-angiogenic potential in chick chorioallantoic membrane (CAM) assay. Int J Biol Macromol, 2024; 281(Pt 3):136373; doi: 10.1016/j.ijbiomac.2024.136373
51.
PrajapatiA, RangraS, PatilR, et al.Receptor-Targeted Nanomedicine for Cancer Therapy. Receptors, 2024; 3(3):323–361.
52.
MogBJ, MarcouN, DiNapoliSR, et al.Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities. Sci Transl Med, 2024; 16(755):eadg7123; doi: 10.1126/scitranslmed.adg7123
53.
ParkE-J, LeeC-W, MedicineM. Soluble receptors in cancer: Mechanisms, clinical significance, and therapeutic strategies. Exp Mol Med, 2024; 56(1):100–109.
54.
AlbuquerqueT, NevesAR, FariaR, et al.Chronobiology and Nanotechnology for Personalized Cancer Therapy. In: Cancer Nanotechnology. Springer: 2022; pp. 205–227.
55.
GhazyE, KumarA, BaraniM, et al.Scrutinizing the therapeutic and diagnostic potential of nanotechnology in thyroid cancer: Edifying drug targeting by nano-oncotherapeutics. J Drug Deliv Sci Technol, 2021; 61:102221.
56.
LiH, FuQ, MuluhTA, et al.The application of nanotechnology in immunotherapy based combinations for cancer treatment. Recent Pat Anticancer Drug Discov, 2023; 18(1):53–65.
57.
YinL, DuanJ-J, BianX-W, et al.Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res, 2020; 22(1):61; doi: 10.1186/s13058-020-01296-5
58.
PupaSM, LigorioF, CancilaV, et al.HER2 signaling and breast cancer stem cells: The bridge behind HER2-positive breast cancer aggressiveness and therapy refractoriness. Cancers (Basel), 2021; 13(19):4778.
59.
LiY, KongX, XuanL, et al.Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment. J Cell Mol Med, 2021; 25(22):10327–10348.
60.
BarchiesiG, MazzottaM, KrasniqiE, et al.Neoadjuvant endocrine therapy in breast cancer: Current knowledge and future perspectives. Int J Mol Sci, 2020; 21(10):3528.
61.
HaoL, DongY, ZhangJ-J, et al.Melatonin decreases androgen-sensitive prostate cancer growth by suppressing SENP1 expression. Transl Androl Urol, 2022; 11(1):91–103.
62.
SartorelliLS, NetoRJB, Mosqueta-PinheiroMG, et al.Blood melatonin level can serve as a potential biomarker for prostate and hepatocellular carcinomas. Melatonin Res, 2021; 4(2):253–269.
63.
MegerianMF, KimJS, BadreddineJ, et al.Melatonin and prostate cancer: Anti-tumor roles and therapeutic application. Aging Dis, 2023; 14(3):840–857.
64.
AlvenS, NqoroX, BuyanaB, et al.Polymer-drug conjugate, a potential therapeutic to combat breast and lung cancer. Pharmaceutics, 2020; 12(5):406.
65.
LiuG, YangL, ChenG, et al.A review on drug delivery system for tumor therapy. Front Pharmacol, 2021; 12:735446; doi: 10.3389/fphar.2021.735446
66.
AzarianM, Ramezani FaraniM, ChoW, et al.Advancements in colorectal cancer treatment: The role of metal-based and inorganic nanoparticles in modern therapeutic approaches. Pathol Res Pract, 2024; 264:155706; doi: 10.1016/j.prp.2024.155706
67.
HaniU, MahammedN, ReshmaT, et al.Enhanced colon-targeted drug delivery through development of 5-fluorouracil-loaded cross-linked mastic gum nanoparticles. Sci Rep, 2025; 15(1):18355; doi: 10.1038/s41598-025-03533-3
68.
TaatiH, SanganiH, DavoudiA, et al.Silver nanoparticle functionalized by glutamine and conjugated with thiosemicarbazide induces apoptosis in colon cancer cell line. Sci Rep, 2024; 14(1):3809; doi: 10.1038/s41598-024-54344-x
69.
IveyGD, JohnstonFM, AzadNS, et al.Current surgical management strategies for colorectal cancer liver metastases. Cancers (Basel), 2022; 14(4):1063.
70.
AlzahraniSM, Al DoghaitherHA, Al-GhafariAB. General insight into cancer: An overview of colorectal cancer. Mol Clin Oncol, 2021; 15(6):271; doi: 10.3892/mco.2021.2433
71.
KhaledYS, KhotMI, Aiyappa-MaudsleyR, et al.Photoactive imaging and therapy for colorectal cancer using a CEA-Affimer conjugated Foslip nanoparticle. Nanoscale, 2024; 16(14):7185–7199; doi: 10.1039/D3NR04118B
72.
ChaiM, WangS, ChenY, et al.Targeted and intelligent nano-drug delivery systems for colorectal cancer treatment. Front Bioeng Biotechnol, 2025; 13:1582659; doi: 10.3389/fbioe.2025.1582659
73.
UnerB, AkyildizEO, KolciK, et al.Nanoparticle Formulations for Intracellular Delivery in Colorectal Cancer Therapy. AAPS PharmSciTech, 2025; 26(3):81; doi: 10.1208/s12249-025-03069-9
74.
ArasS, EfendioğluM, WulamujiangA, et al.Radioprotective effect of melatonin against radiotherapy-induced cerebral cortex and cerebellum damage in rat. Int J Radiat Biol, 2021; 97(3):348–355.
75.
El-MissiryMA, ShabanaS, GhazalaSJ, et al.Melatonin exerts a neuroprotective effect against γ-radiation-induced brain injury in the rat through the modulation of neurotransmitters, inflammatory cytokines, oxidative stress, and apoptosis. Environ Sci Pollut Res Int, 2021; 28(24):31108–31121.
76.
Alonso-GonzálezC, GonzálezA, Menéndez-MenéndezJ, et al.Melatonin as a radio-sensitizer in cancer. Biomedicines, 2020; 8(8):247.
77.
GurunathanS, KangM-H, KimJ-H. Role and therapeutic potential of melatonin in the central nervous system and cancers. Cancers (Basel), 2020; 12(6):1567.
78.
MafiA, RezaeeM, HedayatiN, et al.Melatonin and 5-fluorouracil combination chemotherapy: Opportunities and efficacy in cancer therapy. Cell Commun Signal, 2023; 21(1):33; doi: 10.1186/s12964-023-01047-x
79.
XuL, XuM, SunX, et al.Quantitative comparison of gold nanoparticle delivery via the enhanced permeation and retention (EPR) effect and mesenchymal stem cell (MSC)-based targeting. ACS Nano, 2023; 17(3):2039–2052.
80.
IslamW, NiidomeT, SawaT. Enhanced permeability and retention effect as a ubiquitous and epoch-making phenomenon for the selective drug targeting of solid tumors. J Pers Med, 2022; 12(12):1964.
81.
BaiX, WangY, SongZ, et al.The basic properties of gold nanoparticles and their applications in tumor diagnosis and treatment. Int J Mol Sci, 2020; 21(7):2480.
82.
MoshiriM, MehmannavazF, HashemiM, et al.Evaluation of the efficiency of simvastatin loaded PLGA nanoparticles against acute paraquat-intoxicated rats. Eur J Pharm Sci, 2022; 168:106053.
83.
MediciS, PeanaM, CoradduzzaD, et al.Gold nanoparticles and cancer: Detection, diagnosis and therapy. Elsevier: 2021.
84.
LiuR, LuoC, PangZ, et al.Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chinese Chemical Letters, 2023; 34(2):107518.
85.
SelmaniA, KovačevićD, BohincK. Nanoparticles: From synthesis to applications and beyond. Adv Colloid Interface Sci, 2022; 303:102640.
86.
LimSH, WongTW, TayWX. Overcoming colloidal nanoparticle aggregation in biological milieu for cancer therapeutic delivery: Perspectives of materials and particle design. Adv Colloid Interface Sci, 2024; 325:103094.
87.
GurunathanS, QasimM, KangM-H, et al.Role and therapeutic potential of melatonin in various type of cancers. Onco Targets Ther, 2021; 14:2019–2052.
88.
SamantaS. Melatonin: An endogenous miraculous indolamine, fights against cancer progression. J Cancer Res Clin Oncol, 2020; 146(8):1893–1922.
89.
WangL, WangC, ChoiWS. Use of melatonin in cancer treatment: Where are we? Int J Mol Sci, 2022; 23(7):3779.
90.
MuQ, NajafiM. Modulation of the tumor microenvironment (TME) by melatonin. Eur J Pharmacol, 2021; 907:174365.
91.
TalibWH, AlsayedAR, AbuawadA, et al.Melatonin in cancer treatment: Current knowledge and future opportunities. Molecules, 2021; 26(9):2506.
92.
FrancoPIR, do Carmo NetoJR, MilhomemAC, et al.Antitumor effect of melatonin on breast cancer in experimental models: A systematic review. Biochim Biophys Acta Rev Cancer, 2023; 1878(1):188838.
93.
WangZ, LiuY, MusaAE. Regulation of cell death mechanisms by melatonin: Implications in cancer therapy. Anticancer Agents Med Chem, 2022; 22(11):2080–2090.
94.
NairA. Anticancer properties of melatonin and its role as an adjuvant in cancer treatment. Indian J Cancer, 2022; 59(2):288–294.
95.
Alvarez-ArtimeA, Cernuda-CernudaR, CepasV, et al.Melatonin-induced cytoskeleton reorganization leads to inhibition of melanoma cancer cell proliferation. Int J Mol Sci, 2020; 21(2):548.
96.
AmirhosseinD, RezaA, MehranS, et al.Melatonin as a promising agent for cancer treatment: Insights into its effects on the wnt/beta-catenin signaling pathway. Curr Med Chem, 2024; 31(11):1315–1331; doi: 10.2174/0929867330666230409141957
97.
DasNK, SamantaS. The potential anti-cancer effects of melatonin on breast cancer. Exploration Med, 2022; 3(1):112–127.
98.
YenY-W, LeeY-L, YuL-Y, et al.Fucoidan/chitosan layered PLGA nanoparticles with melatonin loading for inducing intestinal absorption and addressing triple-negative breast cancer progression. Int J Biol Macromol, 2023; 250:126211.
99.
El-FarM, EssamA, FardousF, et al.Synergistic anticancer effect of melatonin and ascorbyl palmitate nanoformulation: A promising combination for cancer therapy. Biointerface Res Appl Chem, 2023; 13(6):596; doi: 10.33263/BRIAC136.596
100.
BalpınarÖ, NadaroğluH, HacımüftüoğluA. Green synthesis, characterization of melatonin-like drug bioconjugated CoS quantum dots and its antiproliferative effect on different cancer cells. Mol Biol Rep, 2023; 50(11):9143–9151.
101.
ShirzadM, DaraeiA, NajafzadehvarziH, et al.Apoptosis triggering in breast cancer cells with co-delivery of melatonin and doxorubicin loaded into human adipose mesenchymal stem cell derived exosomes. Res Sq, 2024; doi: 10.21203/rs.3.rs-3906438/v1
102.
Ince‐ErgucE, DurgunK, AkdemirA, et al.Design, synthesis, and investigation of anticancer and antioxidant potential of novel indole‐based melatonin analogues in breast cancer. ChemistrySelect, 2024; 9(25):e202400817; doi: 10.1002/slct.202400817
103.
RohillaS, SinghM, PriyaS, et al.Exploring the mechanical perspective of a new anti-tumor agent: Melatonin. J Environ Pathol Toxicol Oncol, 2023; 42(1):1–16.
104.
JafariH, HassanpourM, AkbariA, et al.Characterization of pH-sensitive chitosan/hydroxypropyl methylcellulose composite nanoparticles for delivery of melatonin in cancer therapy. Mater Lett, 2021; 282:128818.
105.
ParvezS, YadagiriG, AroraK, et al.Coalition of biological agent (melatonin) with chemotherapeutic agent (amphotericin B) for combating visceral leishmaniasis via oral administration of modified solid lipid nanoparticles. ACS Biomater Sci Eng, 2023; 9(6):2902–2910.
106.
SohailS, ShahFA, Uz ZamanS, et al.Melatonin delivered in solid lipid nanoparticles ameliorated its neuroprotective effects in cerebral ischemia. Heliyon, 2023; 9(9):e19779; doi: 10.1016/j.heliyon.2023.e19779
107.
SiahdashtFN, FarhadianN, KarimiM, et al.Enhanced delivery of melatonin loaded nanostructured lipid carriers during in vitro fertilization: NLC formulation, optimization and IVF efficacy. RSC Adv. 2020; 10(16):9462–9475.
108.
Mirza-Aghazadeh-AttariM, MihanfarA, YousefiB, et al.Nanotechnology-based advances in the efficient delivery of melatonin. Cancer Cell Int, 2022; 22(1):43.
109.
ChuffaL, SeivaFRF, NovaisAA, et al.Melatonin-loaded nanocarriers: New horizons for therapeutic applications. Molecules, 2021; 26(12):3562.
110.
FrancoPI, do Carmo NetoJR, RochaVL, et al.A revision of polymeric nanoparticles as a strategy to improve the biological activity of melatonin. CMC, 2023; 30(29):3315–3334; doi: 10.2174/0929867329666221006113536
111.
SiM, SunQ, DingH, et al.Melatonin‐loaded nanoparticles for enhanced antidepressant effects and HPA hormone modulation. Advances in Polymer Technology, 2020; 2020(1):1–9.
112.
AkbarzadehM, VahedianV, Hamid AbudulmohesenZ, et al.The evaluation of Melatonin and EGF interaction on breast cancer metastasis. Horm Mol Biol Clin Investig, 2024:119–130; doi: 10.1515/hmbci-2023-0082
113.
YangSF, ChenYS, ChienHW, et al.Melatonin attenuates epidermal growth factor‐induced cathepsin S expression in ARPE‐19 cells: Implications for proliferative vitreoretinopathy. J Pineal Res, 2020; 68(1):e12615.
114.
MorenoACR, de Freitas SaitoR, TiagoM, et al.Melatonin inhibits human melanoma cells proliferation and invasion via cell cycle arrest and cytoskeleton remodeling. Melatonin Res, 2020; 3(2):194–209.
115.
MdkhanaB, GoelS, SalehM, et al.Role of oxidative stress in angiogenesis and the therapeutic potential of antioxidants in breast cancer. Eur Rev Med Pharmacol Sci, 2022; 26(13):4677–4692; doi: 10.26355/eurrev_202207_29192
116.
KhodabandehZ, ValiloM, VelaeiK, et al.The potential role of nicotine in breast cancer initiation, development, angiogenesis, invasion, metastasis, and resistance to therapy. Breast Cancer, 2022; 29(5):778–789.
117.
Abd El-SalamM, El-TanboulyG, BastosJ, et al.Suppression of VEGF and inflammatory cytokines, modulation of Annexin A1 and organ functions by galloylquinic acids in breast cancer model. Sci Rep, 2023; 13(1):12268.
118.
ÖnderGÖ, SezerG, ÖzdamarS, et al.Melatonin has an inhibitory effect on MCF‐7 and MDA‐MB‐231 human breast cancer cell lines by inducing autophagy and apoptosis. Fundam Clin Pharmacol, 2022; 36(6):1038–1056.
119.
MaroufiNF, AshouriN, MortezaniaZ, et al.The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor. Pathol Res Pract, 2020; 216(10):153226.
120.
FigueroaEG, González-CandiaA, Caballero-RománA, et al.Blood-brain barrier dysfunction in hemorrhagic transformation: A therapeutic opportunity for nanoparticles and melatonin. J Neurophysiol, 2021; 125(6):2025–2033.
121.
BiswalL, SardoiwalaMN, KushwahaAC, et al.Melatonin-Loaded Nanoparticles Augment Mitophagy to Retard Parkinson’s Disease. ACS Appl Mater Interfaces, 2024; 16(7):8417–8429.
122.
MoroniI. Absorption and pharmacokinetic studies of melatonin using polymer-coated drug delivery systems. Macquarie University; 2022.
123.
YangJ, TangQ, ZengY. Melatonin: Potential avenue for treating iron overload disorders. Ageing Res Rev, 2022; 81:101717.
124.
SchettigR, SearsT, KleinM, et al.Melatonin: A powerful integrative adjunctive agent for oncology. JCT, 2020; 11(09):571–596.
125.
KaradasAK, DilmacS, AytacG, et al.Melatonin decreases metastasis, primary tumor growth and angiogenesis in a mice model of breast cancer. Hum Exp Toxicol, 2021; 40(9):1545–1557.
126.
WangSW, TaiHC, TangCH, et al.Melatonin impedes prostate cancer metastasis by suppressing MMP‐13 expression. J Cell Physiol, 2021; 236(5):3979–3990.
127.
GuH, ShenQ, MeiD, et al.Melatonin inhibits TE-1 esophageal cancer cells metastasis by suppressing the NF-κB signaling pathway and decreasing MMP-9. Ann Clin Lab Sci, 2020; 50(1):65–72.
128.
MehrzadiS, KarimiMY, FatemiA, et al.SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: Beneficial effects of melatonin. Pharmacol Ther, 2021; 224:107825.
129.
MohanbhaiSJ, SardoiwalaMN, GuptaS, et al.Colon targeted chitosan-melatonin nanotherapy for preclinical Inflammatory Bowel Disease. Biomater Adv, 2022; 136:212796.
130.
YenerS, AkbulutKG, KarakuşR, et al.Development of melatonin loaded pectin nanoparticles for the treatment of inflammatory bowel disease: In vitro and in vivo studies. J Drug Deliv Sci Technol, 2022; 67:102861.
131.
RodríguezC, Puente‐MoncadaN, ReiterRJ, et al.Regulation of cancer cell glucose metabolism is determinant for cancer cell fate after melatonin administration. J Cell Physiol, 2021; 236(1):27–40.
132.
ReiterRJ, SharmaR, Rosales-CorralS, et al.Melatonin and pathological cell interactions: Mitochondrial glucose processing in cancer cells. Int J Mol Sci, 2021; 22(22):12494.
133.
KondapiAK. Targeting cancer with lactoferrin nanoparticles: Recent advances. Nanomedicine (Lond), 2020; 15(21):2071–2083.
134.
TranTH, TranPTT, TruongDH. Lactoferrin and nanotechnology: The potential for Cancer treatment. Jp, 2023; 15(5):1362.
135.
PanS, WengH, HuG, et al.Lactoferrin may inhibit the development of cancer via its immunostimulatory and immunomodulatory activities. Int J Oncol, 2021; 59(5):85; doi: 10.3892/ijo.2021.5265
136.
ShuX, SuJ, ZhaoY, et al.Regulation of HeLa cell proliferation and apoptosis by bovine lactoferrin. Cell Biochem Funct, 2023; 41(8):1395–1402.
137.
OlszewskaP, PazdrakB, KruzelML. A novel human recombinant lactoferrin inhibits lung adenocarcinoma cell growth and migration with no cytotoxic effect on normal human epithelial cells. Arch Immunol Ther Exp (Warsz), 2021; 69(1):33.
138.
El-FakharanyEM, Abu-SerieMM, HabashyNH, et al.Augmenting apoptosis-mediated anticancer activity of lactoperoxidase and lactoferrin by nanocombination with copper and iron hybrid nanometals. Sci Rep, 2022; 12(1):13153.
139.
ZhangZ, LuM, ChenC, et al.Holo-lactoferrin: The link between ferroptosis and radiotherapy in triple-negative breast cancer. Theranostics, 2021; 11(7):3167–3182.
140.
ElzoghbyAO, AbdelmoneemMA, HassaninIA, et al.Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier & targeting ligand. Biomaterials, 2020; 263:120355.
141.
Ramírez-RicoG, Drago-SerranoME, León-SicairosN, et al.Lactoferrin: A nutraceutical with activity against colorectal cancer. Front Pharmacol, 2022; 13:855852.
142.
AgwaMM, SabraS. Lactoferrin coated or conjugated nanomaterials as an active targeting approach in nanomedicine. Int J Biol Macromol, 2021; 167:1527–1543.
143.
AliOM, BekhitAA, KhattabSN, et al.Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy. Colloids Surf B Biointerfaces, 2020; 188:110824.
144.
AlyS, El-KamelAH, ShetaE, et al.Chondroitin/Lactoferrin-dual functionalized pterostilbene-solid lipid nanoparticles as targeted breast cancer therapy. Int J Pharm, 2023; 642:123163.
145.
Hernández-GaldámezHV, Fattel-FazendaS, Flores-TéllezTN, et al.Iron-saturated bovine lactoferrin: A promising chemopreventive agent for hepatocellular carcinoma. Food Funct, 2024; 15(8):4586–4602.
146.
JiangW, CaoX, GuanY, et al.Fabrication of fucoxanthin-loaded composite nanoparticles based on lactoferrin and carboxymethyl chitosan: Interaction mechanism, stability and the application in filled hydrogel beads. Food Res Int, 2025; 214:116614; doi: 10.1016/j.foodres.2025.116614
147.
SunS, ZongW, JiangL, et al.Protective effects and mechanisms of lactoferrin and HIF-1α on dry eye syndrome in mice. Exp Eye Res, 2025; 255:110339; doi: 10.1016/j.exer.2025.110339
148.
GavasS, QuaziS, KarpińskiTM. Nanoparticles for cancer therapy: Current progress and challenges. Nanoscale Res Lett, 2021; 16(1):173.
149.
ZhangM, GaoS, YangD, et al.Influencing factors and strategies of enhancing nanoparticles into tumors in vivo. Acta Pharm Sin B, 2021; 11(8):2265–2285.
150.
EjigahV, OwoseniO, Bataille-BackerP, et al.Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. Polymers (Basel), 2022; 14(13):2601.
151.
SharifiM, ChoWC, AnsariesfahaniA, et al.An updated review on EPR-based solid tumor targeting nanocarriers for cancer treatment. Cancers (Basel), 2022; 14(12):2868.
152.
IzciM, MaksoudianC, ManshianBB, et al.The use of alternative strategies for enhanced nanoparticle delivery to solid tumors. Chem Rev, 2021; 121(3):1746–1803.
153.
MohammadzadehV, RahimanN, HosseinikhahSM, et al.Novel EPR-enhanced strategies for targeted drug delivery in pancreatic cancer: An update. J Drug Deliv Sci Technol, 2022; 73:103459.
154.
ValcourtDM, KapadiaCH, ScullyMA, et al.Best practices for preclinical in vivo testing of cancer nanomedicines. Adv Healthc Mater, 2020; 9(12):2000110.
155.
ChiangC-L, ChengM-H, LinC-H. From nanoparticles to cancer nanomedicine: Old problems with new solutions. Nanomaterials (Basel), 2021; 11(7):1727.
156.
de LázaroI, MooneyD. Obstacles and opportunities in a forward vision for cancer nanomedicine. Nat Mater, 2021; 20(11):1469–1479.
157.
MujC, MukhopadhyayS, JanaP, et al.Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer. Cancer Chemother Pharmacol, 2023; 91(5):375–387.
158.
AbdelmoneemMA, Abd ElwakilMM, KhattabSN, et al.Lactoferrin-dual drug nanoconjugate: Synergistic anti-tumor efficacy of docetaxel and the NF-κB inhibitor celastrol. Mater Sci Eng C Mater Biol Appl, 2021; 118:111422.
159.
El-FakharanyEM, Abu-SerieMM, IbrahimA, et al.Anticancer activity of lactoferrin-coated biosynthesized selenium nanoparticles for combating different human cancer cells via mediating apoptotic effects. Sci Rep, 2023; 13(1):9579; doi: 10.1038/s41598-023-36492-8
160.
YuanL, ChenQ, RiviereJE, et al.Pharmacokinetics and tumor delivery of nanoparticles. J Drug Deliv Sci Technol, 2023; 83:104404; doi: 10.1016/j.jddst.2023.104404
161.
XuanL, JuZ, SkoniecznaM, et al.Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models. MedComm (2020), 2023; 4(4):e327; doi: 10.1002/mco2.327
162.
WahnouH, El KebbajR, HbaS, et al.Neutrophils and neutrophil-based drug delivery systems in anti-cancer therapy. Cancers (Basel), 2025; 17(7):1232; doi: 10.3390/cancers17071232
163.
MunJG, WangD, Doerflein FulkDL, et al.A randomized, double-blind, crossover study to investigate the pharmacokinetics of extended-release melatonin compared to immediate-release melatonin in healthy adults. J Diet, 2024; 21(2):182–194; doi: 10.1080/19390211.2023.2206475
164.
AdiguzelS, KarameseM, KuguS, et al.Doxorubicin-loaded liposome-like particles embedded in chitosan/hyaluronic acid-based hydrogels as a controlled drug release model for local treatment of glioblastoma. Int J Biol Macromol, 2024; 278(Pt 4):135054; doi: 10.1016/j.ijbiomac.2024.135054
165.
ZumayaALV, PavlíčkováVS, RimpelováS, et al.PLGA-based nanocarriers for combined delivery of colchicine and purpurin 18 in cancer therapy: Multimodal approach employing cancer cell spheroids. Int J Pharm, 2024; 657:124170; doi: 10.1016/j.ijpharm.2024.124170
166.
TruongTT, MondalS, DoanVHM, et al.Precision-engineered metal and metal-oxide nanoparticles for biomedical imaging and healthcare applications. Adv Colloid Interface Sci, 2024; 332:103263; doi: 10.1016/j.cis.2024.103263
167.
SunB, ChenH, WangY, et al.Development of mesoporous silica-based nanoparticles for cancer phototherapy. Dyes and Pigments, 2024; 222:111881; doi: 10.1016/j.dyepig.2023.111881
168.
CaoZ, ZuoX, LiuX, et al.Recent progress in stimuli-responsive polymeric micelles for targeted delivery of functional nanoparticles. Adv Colloid Interface Sci, 2024; 330:103206; doi: 10.1016/j.cis.2024.103206
169.
BarmoudehZ, FouaniMH, MoslemiZ, et al.Melatonin and metformin co-loaded nanoliposomes efficiently attenuate liver damage induced by bile duct ligation in rats. Naunyn Schmiedebergs Arch Pharmacol, 2024; 397(1):395–410.
170.
Clinical Evaluation of Melatonin Concomitant Use With Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients. 2025.
171.
Impact of Melatonin Supplementation Plus Exercise Program in Women Who Have Suffered from Breast Cancer in the Province of Soria, Spain. 2024.
172.
NasrAAM, FathyMK, AhmadRAA. Lactoferrin Alone Vs Iron Alone Vs Lactoferrin Plus Iron for Treatment of Iron Deficiency Anemia During the 3rd Trimester of Pregnancy (Randomized Controlled Trial). Evidence Based Women s Health Journal, 2024; 15(15):1–7; doi: 10.21608/ebwhj.2025.348714.1412
SharifiM, JafariS, HasanA, et al.Antimetastatic activity of lactoferrin-coated mesoporous maghemite nanoparticles in breast cancer enabled by combination therapy. ACS Biomater Sci Eng, 2020; 6(6):3574–3584.
175.
ThomasEM, WrightJA, BlakeSJ, et al.Advancing translational research for colorectal immuno-oncology. Br J Cancer, 2023; 129(9):1442–1450; doi: 10.1038/s41416-023-02392-x
176.
DurinikovaE, BuzoK, ArenaS. Preclinical models as patients’ avatars for precision medicine in colorectal cancer: Past and future challenges. J Exp Clin Cancer Res, 2021; 40(1):185; doi: 10.1186/s13046-021-01981-z
177.
RassuG, SorrentiM, CatenacciL, et al.Conjugation, prodrug, and co-administration strategies in support of nanotechnologies to improve the therapeutic efficacy of phytochemicals in the central nervous system. Pharmaceutics, 2023; 15(6):1578.
178.
SharmaA, JangraN, DheerD, et al.Understanding the journey of biopolymeric nanoformulations for oral drug delivery: Conventional to advanced treatment approaches. Eur Polym J, 2024; 218:113338.
179.
El-FakharanyEM. Nanoformulation of lactoferrin potentiates its activity and enhances novel biotechnological applications. Int J Biol Macromol, 2020; 165(Pt A):970–984.
180.
ZhangH, XuH-L, WangY-C, et al.20 (S)-Protopanaxadiol-induced apoptosis in MCF-7 breast cancer cell line through the inhibition of PI3K/AKT/mTOR signaling pathway. IJMS, 2018; 19(4):1053; doi: 10.3390/ijms19041053
181.
ChehelgerdiM, ChehelgerdiM, AllelaOQB, et al.Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation. Mol Cancer, 2023; 22(1):169.
182.
KaraG, CalinGA, OzpolatB. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev, 2022; 182:114113.
183.
DengW, ShangH, TongY, et al.The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy. J Nanobiotechnology, 2024; 22(1):97.
184.
KongX, QiY, WangX, et al.Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer. Prog Mater Sci, 2023; 134:101070.
185.
Sedighi PashakiA, MohammadianK, AfsharS, et al.A randomized, controlled, parallel-group, trial on the effects of melatonin on fatigue associated with breast cancer and its adjuvant treatments. Integr Cancer Ther, 2021; 20:1534735420988343.
186.
Jafari-KoulaeeA, Bagheri-NesamiMJSM. The effect of melatonin on sleep quality and insomnia in patients with cancer: A systematic review study. Sleep Med, 2021; 82:96–103.
187.
SinopoliA, IsonneC, SantoroMM, et al.The effects of orally administered lactoferrin in the prevention and management of viral infections: A systematic review. Rev Med Virol, 2022; 32(1):e2261; doi: 10.1002/rmv.2261
188.
WangS, ChengK, ChenK, et al.Nanoparticle-based medicines in clinical cancer therapy. Nano Today, 2022; 45:101512.
189.
EtedaliA, HosseniAK, DerakhshandehA, et al.Melatonin in the management of mood and sleep problems induced by androgen deprivation therapy in prostate cancer patients: A randomized double-blinded, placebo-controlled clinical trial. Iran J Pharm Res, 2022; 21(1):e128817; doi: 10.5812/ijpr-128817
190.
YangF, XueJ, WangG, et al.Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Front Pharmacol, 2022; 13:999404.
191.
ThakuriaA, KatariaB, GuptaD. Nanoparticle-based methodologies for targeted drug delivery—an insight. JJoNR, 2021; 23(4):87.
192.
BajpaiS, TiwarySK, SonkerM, et al.Recent advances in nanoparticle-based cancer treatment: A review. ACS Appl Nano Mater, 2021; 4(7):6441–6470.
193.
YetisginAA, CetinelS, ZuvinM, et al.Therapeutic nanoparticles and their targeted delivery applications. Molecules, 2020; 25(9):2193.
194.
XuH, ZhaoH, DingC, et al.Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1. Signal Transduct Target Ther, 2023; 8(1):51; doi: 10.1038/s41392-022-01231-4
195.
RaduP, ZurzuM, TigoraA, et al.The Impact of Cancer Stem Cells in Colorectal Cancer. Int J Mol Sci, 2024; 25(8):4140; doi: 10.3390/ijms25084140
